我国药品生产企业信用监管法制建设存在的问题及对策研究  

Research on Problems and Countermeasures of Credit Supervision Laws and Regulations Construction of Drug Production Enterprises in China

作　　者：栾力介 田丽娟[1] Luan Lijie;Tian Lijuan(School of Business Administration,Shenyang Pharmaceutical University,Shenyang 110016,China)

机构地区：[1]沈阳药科大学工商管理学院,沈阳110016

出　　处：《中国药事》2024年第8期853-859,共7页Chinese Pharmaceutical Affairs

摘　　要：目的:为完善我国药品生产企业信用监管法制建设,提高我国药品生产企业诚信意识,促进诚信生产活动提供建议与参考。方法:通过对我国药品生产企业信用监管法制建设的研究,分析其存在的问题并提出合理化建议。结果与结论:我国药品生产企业信用监管法制建设尚不完善,主要体现在信用奖惩机制尚不健全,联合惩戒机制还不完善;信用等级评定办法缺乏具体和统一的标准;信用信息公开披露的规定不够具体;医药行业协会作用发挥不充分等。基于此,从信用奖惩机制、信用等级评定制度、信用信息公开披露制度与外部支撑体系作用4个方面提出对应的建议,以加强我国药品生产企业信用监管法制建设。Objective:To improve the laws and regulations construction of credit supervision of drug production enterprises,improve the integrity awareness of drug production enterprises in China,and provide suggestions and references for promoting integrity production activities.Methods:The existing problems were analyzed and reasonable suggestions were put forward through research on the construction of credit supervision laws and regulations of drug production enterprises in China.Results and Conclusion:China's drug production enterprise credit supervision laws and regulations construction was not perfect,mainly reflected in the credit reward and punishment mechanism was not perfect,the joint punishment mechanism was not perfect;the credit rating method lacked specific and unified standards;the provisions on the disclosure of credit information were not specific enough;the role of the pharmaceutical industry association was not fully played.Based on this,this paper puts forward corresponding suggestions from four aspects:credit reward and punishment mechanism,credit rating evaluation system,credit information disclosure system and external support system,so as to strengthen the laws and regulations construction of credit supervision of drug production enterprises in China.

关 键 词：药品安全 药品生产企业 诚信 信用监管 法制建设 

分 类 号：R95[医药卫生—药学]